Lytix Biopharma AS announces that LTX-315 with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with metastatic soft tissue sarcoma (STS). ...Middle East

OSLO, Norway, June 5, 2022 /PRNewswire/ -- Lytix Biopharma AS ("Lytix" or the "Company"), a clinical-stage company with an in situ vaccination technology platform, today announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma (STS). The data...

Hence then, the article about lytix biopharma as announces that ltx 315 with adoptive cell therapy has been shown to generate tumor specific t cells and stabilize the disease in patients with metastatic soft tissue sarcoma sts was published today ( Sunday 05/06/2022 - 07:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lytix Biopharma AS announces that LTX-315 with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with metastatic soft tissue sarcoma (STS). )

Also on site :

• Cruise ship boss sues P&O for massive £9.7m over claims slip in toilet ended career
• US will take Greenland because of European ‘weakness’ – treasury secretary
• UK vows not to yield to Trump on Greenland